Objective. The purpose of this study was to assess the diagnostic performance of real-time contrastenhanced sonography in characterization of small focal liver lesions (FLLs; ≤3.0 cm in diameter). Methods. Two hundred small FLLs in 200 patients were examined by contrast-enhanced sonography using a contrastspecific mode of contrast pulse sequencing and a sulfur hexafluoride-filled microbubble contrast agent. The sonographic images were reviewed by 2 independent readers. A 5-point confidence level was used to discriminate malignant from benign FLLs, and specific diagnoses were recorded. The diagnostic performances were evaluated by receiver operating characteristic (ROC) analysis, and the interobserver agreement was analyzed by weighted κ statistics. Results. After review of contrast-enhanced sonography, ROC analysis revealed significant improvement in differentiating between malignant and benign small FLLs that the areas under the ROC curve were 0.856 at baseline sonography versus 0.954 at contrast-enhanced sonography for reader 1 (P < .001) and 0.857 versus 0.954 for reader 2 (P = .003). The sensitivity, negative predictive value, and accuracy for both readers also improved significantly after contrast agent administration (all P < .001). A better result of specific diagnosis was obtained (38.5% [77/200] he number of small focal liver lesion (FLLs) 3.0 cm or less in diameter has greatly increased in clinical practice because of the extensive use of abdominal imaging procedures in both screened and unscreened populations. Determining the natures of these lesions is crucial for treatment planning. [1][2][3][4] However, differentiation between malignancy and benignity for small FLLs may be uncertain for sonography in most of the cases. Even with the information derived from clinical and biochemical data, together with those derived from other imaging techniques, sometimes it is still hard to make a definite diagnosis because many small FLLs may not show typical manifestations on other imaging modalities, and serum tumor marker may not arise in some patients with hepatocellular carcinoma (HCC) or liver metastasis.2-5 In a recent study, Rickes et al 6 found that about 50% of nodules of HCC and 40% of